Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on November 3, 2004. The filing addresses a material definitive agreement regarding the extension of a lockup period associated with the company's underwriting agreement dated May 27, 2004.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and securities agreements rather than financial performance data.
Material Changes
- Lockup Extension: Alnylam agreed to extend its 180-day lockup agreement with Banc of America Securities LLC, Citigroup Global Markets Inc., Piper Jaffray & Co., and ThinkEquity Partners LLC by an additional 8 days.
- New Expiration Date: The lockup period now runs through and including December 1, 2004.
- Scope: The extension applies to all officers, directors, stockholders, and option holders who previously executed lockup agreements.
Outlook, Commentary, and Risks
Management Commentary: The extension was implemented to permit research analysts to publish or distribute research reports and make public appearances concerning Alnylam in accordance with National Association of Securities Dealers, Inc. rules. This timing aligns with the announcement of the company's third-quarter financial results scheduled for November 10, 2004.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the standard restrictions imposed by the extended lockup agreement.
Investor Verification Checklist
- Verify the exact expiration date of the lockup agreement (December 1, 2004).
- Confirm the scheduled date for the third-quarter financial results announcement (November 10, 2004).
- Review the original Underwriting Agreement dated May 27, 2004, to understand the baseline terms before this amendment.
- Check subsequent filings for the actual third-quarter financial results to assess the company's financial health.